New Myeloma Diagnostic Criteria: To Treat or Not to Treat? Monocentric Experience of 220 Newly Multiple Myeloma Diagnosed Patients Retrospectively Analyzed

作者
Lorenza Torti,Stefano Pulini,Anna Maria Morelli,Francesco Bacci,Paolo Di Bartolomeo
出处
期刊:Blood [Elsevier BV]
卷期号:128 (22): 5629-5629 被引量:1
标识
DOI:10.1182/blood.v128.22.5629.5629
摘要

Abstract Newly significant advances have been made in diagnosis and treatment of multiple-myeloma (MM).Until recently,MM was defined by presence of end-organ-damage,specifically hypercalcemia, renal-failure, anemia and bone-lesions(CRAB-features). International-Myeloma-Working-Group(IMWG)revised diagnostic-criteria adding three specific-markers:clonal-bone-marrow-plasma-cells greater than 60%, serum-free-light-chain-ratio (FLC)more than 100 and at least two focal-lesions on magnetic-resonance-imaging(MRI). After this update,it's now time to change therapeutic-paradigm: new-IMWG-guidelines allow earlier intervention without waiting end-organ-damage to treat . Nevertheless there is much to learn and share about these new standards that change treatment. When is the right-time to start therapy?We have tried to answer to this dilemma in our work comparing traditional-CRAB-features with recent-myeloma-diagnostic-criteria in a group of 220 newly-diagnosed-MM followed in our Department from 1999 to 2015. The aim of our retrospective-study was to analyze development of new-IMWG-biomarkers during disease-course before CRAB-events and beginning-treatment,discussing their strengths and weaknesses as well as lights and shadows. We evaluated 110 young-patients elegible for high-dose-chemotherapy and autologous-stem-cell-transplant(ASCT)and 110 old(more than 65-year-old)treated with different-kind of therapies. We highlighted presence of IMWG-new-criteria as myeloma-defining-events(MDEs) before CRAB-markers in 44 MM-patients (20% of all): 33 of them are old (median-age of 72 years,range 53-91)and 11 are young (median-age 57,range 41-65) and treated with transplant-procedure. In details most of them presented FLC ratio >100 (30 patients as 68% of this subgroup), following by MRI-lesions(10 patients as 23%) and lastly plasma-cells-bone-marrow-involvement greater of 60%(4 patients as 9%). The majority of these patients (39 as 89%) developed CRAB-characteristics after six months (median value, range 3-15) and have evolved in myeloma-requesting-treatment in less than a year. 27 of them have IgG, 12 IgA and 5 micromolecular-MM. The largest-part (40 patients)has an antecedent MGUS and smouldering-MM.Moreover five young-patients of the whole-population analysed with MDEs and good-clinical-status weren't treated based-on our clinical-judgement and continued close-observation,saving them from both early-therapeutic-toxicity and clonal-selection. Only two patients of 220 started treatment based-on new-IMWG-biomarkers,presenting with clinical-deterioration and increase in monoclonal-component. In conclusion our paper proved that movement from symptoms to biomarkers is a huge-step-forward expecially for elderly-patients,considering both clinical-signs and biological-features. However we need more pratical-implementation of new markers that are changing philosophy of treatment: these patients should be offered appropriate clinical-trial. More caution is needed in high-risk-group expecially young to avoid an overtreating-policy,considering also counter-arguments. Physicians should continue monitoring patients using tools- now-available,while waiting for results from future-prospective-studies. Increase of monoclonal-componenent was analysed not as CRAB-classic-criterion but like disease-marker. The time-difference between new -IMWG-criteria and CRAB-events is less than one year (mean-value 6 months). Figure 1 New-IMWG-criteria-versus-traditional-CRAB. We have studied in our 44-patients with new-diagnostic-markers,time-course of hemoglobin, monoclonal-protein and creatinine-values. Figure 1. New-IMWG-criteria-versus-traditional-CRAB. We have studied in our 44-patients with new-diagnostic-markers,time-course of hemoglobin, monoclonal-protein and creatinine-values. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ssk发布了新的文献求助10
刚刚
刚刚
danny完成签到,获得积分10
刚刚
NN的应助被小邹采纳,获得10
1秒前
1秒前
2秒前
饲料批发的应助被川沧采纳,获得10
3秒前
姚序东完成签到,获得积分10
3秒前
4秒前
4秒前
5秒前
号左左发布了新的文献求助50
5秒前
九九发布了新的文献求助10
6秒前
7秒前
xing_xing的应助被曾经的剑身采纳,获得20
7秒前
超级无敌发布了新的文献求助10
7秒前
zzz发布了新的文献求助10
7秒前
yz1005完成签到,获得积分10
7秒前
Lucas的应助被胡萝卜卜采纳,获得10
7秒前
反证谁能想的到完成签到,获得积分10
8秒前
9秒前
研友_nongdalyl完成签到,获得积分10
9秒前
10秒前
11秒前
榴莲气泡水完成签到 ,获得积分10
13秒前
13秒前
今后的应助被DionysusR采纳,获得10
13秒前
YY关注了科研通微信公众号
13秒前
ttttttt发布了新的文献求助10
14秒前
15秒前
香蕉觅云的应助被rachel采纳,获得10
15秒前
promise发布了新的文献求助10
15秒前
盛小珊完成签到,获得积分10
16秒前
齐xia完成签到 ,获得积分10
17秒前
William_l_c发布了新的文献求助50
17秒前
ff发布了新的文献求助10
17秒前
Akim的应助被Libra采纳,获得10
17秒前
zhanglx66完成签到 ,获得积分10
18秒前
19秒前
WU哇哇完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191140
求助须知:如何正确求助?哪些是违规求助? 9578110
关于积分的说明 21856695
捐赠科研通 7790440
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560328
邀请新用户注册赠送积分活动 2483288